Home › Compare › HOYFF vs ABBV
HOYFF yields 3.67% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, HOYFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HOYFF + ABBV for your $10,000?
Huhtamäki Oyj manufactures and sells packaging products in the United States, Germany, India, the United Kingdom, Australia, Thailand, China, South Africa, Russia, the United Arab Emirates, Findland, and internationally. It operates in foodservice packaging, flexible packaging, and fiber packaging business areas. The company offers single and double-wall paper cups, coffee cups, cold drinks cups, cup carriers, lids, accessories, and short run prints of customized paper cups; take away trays, containers, clamshells, scoops, bowls, wraps, and various accessories for take-away and dining; and egg trays, egg cartons, fruit trays, and wine bottle separators. It also provides multilayer films, wrappers, labels, pouches, and various reclose and print options for coffee, tea, juice, energy drink, and alcoholic beverage packaging; and stand up pouches, food pouches, multilayer packaging, and foils for ice cream, soups, biscuits, confectionary, dry foods, and other retail foods. In addition, the company offers ready-to-eat pet food packaging, such as retort pouches and barrier laminates, as well as open and reclosable bags, and pouches in aluminum foil and non-foil transparent structures; packaging and labels for personal and home care products; tube laminates for toothpaste and other tubes; and blister packaging materials and pharmaceutical packaging. Further, it provides catering disposables and vending cups; food service paper and disposable tableware to foodservice operators, fast food restaurants, and coffee shops; packaging solutions for retail business; flexible packaging solutions. Huhtamäki Oyj was founded in 1920 and is headquartered in Espoo, Finland.
Full HOYFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.